Last reviewed 2026-04-20 · How we verify

Ancytabine (ANCITABINE)

Phase 2 active Small molecule

Ancytabine (generic name: ANCITABINE) is a ancitabine drug. It is currently in Phase 2 development.

Ancytabine is a nucleoside analog that works by inhibiting DNA synthesis, thereby preventing cancer cell growth.

Ancytabine (ANCITABINE) is a small molecule drug in the ancitabine class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are unknown. Ancytabine has not been approved by the FDA for any indications. Its commercial status, half-life, bioavailability, generic manufacturers, and off-patent status are also unknown. As a result, there is limited information available on this compound.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 2 attrition -2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ANCITABINE
Drug class	ancitabine
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like factories that make copies of themselves. Ancytabine is a special molecule that gets inside these factories and blocks the machines that make new copies, preventing the cancer cells from growing and dividing.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ancytabine CI brief — competitive landscape report
Ancytabine updates RSS · CI watch RSS

Frequently asked questions about Ancytabine

What is Ancytabine?

Ancytabine (ANCITABINE) is a ancitabine drug.

How does Ancytabine work?

Ancytabine is a nucleoside analog that works by inhibiting DNA synthesis, thereby preventing cancer cell growth.

What is the generic name of Ancytabine?

ANCITABINE is the generic (nonproprietary) name of Ancytabine.

What drug class is Ancytabine in?

Ancytabine belongs to the ancitabine class. See all ancitabine drugs at /class/ancitabine.

What development phase is Ancytabine in?

Ancytabine is in Phase 2.

Drug class: All ancitabine drugs
Therapeutic area: All drugs in Oncology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing